Celsion and Medidata to Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial
06 avr. 2022 08h30 HE
|
Celsion Corporation
Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients to be presented at 2022 AACR Annual Meeting being held April 8-13 in New Orleans, LA LAWRENCEVILLE, N.J., April...